Bioxcel therapeutics provides update on recent developments for late-stage clinical programs and expansion of ip portfolio for igalmi™ (dexmedetomidine) sublingual film

Meetings scheduled with fda in october and november for tranquility and serenity iii programs company strengthens igalmi ™ market exclusivity through receipt of two notices of allowance new haven, conn., oct. 04, 2023 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience, today provided an update on recent developments with its late-stage clinical programs as well as its patent portfolio for igalmi™ (dexmedetomidine) sublingual film.
BTAI Ratings Summary
BTAI Quant Ranking